| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Division of Endocrinology and Metabolism (B.G., E.A.S., W.H.D.), University of California, San Diego, La Jolla, California 92093; Department of Physiology and Biophysics (G.G.) and Department of Cell and Developmental Biology (A.S.M.), ICB University of Sao Paulo, 05508-900 Sao Paulo, Brazil; and Departments of Pharmaceutical Chemistry and Cellular and Molecular Pharmacology (G.C., T.S., J.D.B.), University of California, San Francisco, San Francisco, California 94143
Address all correspondence and requests for reprints to: Wolfgang H. Dillmann, Division of Endocrinology and Metabolism, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093-0618. E-mail: wdillman{at}ucsd.edu.
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
and TRß mediate T3 signaling in a variety of organs including the heart. The contractile function of the heart is markedly influenced by alterations of the thyroid status (1, 2). In particular, a delay in diastolic relaxation occurs with hypothyroidism, and this change can be linked to a delay in the calcium transient during the contractile cycle. One of the important mediators of calcium flux is the activity of the calcium ATPase of the sarcoplasmic reticulum (SERCa2), and the expression of this gene in cardiac myocytes is markedly influenced by thyroid hormone (T3) levels (3). We previously analyzed the enhancer and promoter region of the SERCa2 gene and identified three separate thyroid hormone response elements (TREs) in the region extending 500 nucleotides upstream from the transcription start (4). TRE1 is a direct repeat spaced by four nucleotides (DR4) and is localized between –481 and –458. TRE2 is an inverted palindrome, also termed everted repeat element, spaced by four nucleotides between –310 and –289. TRE3 is also an inverted palindrome but is spaced by six nucleotides and is localized between –218 and –195. It is currently unclear what functional contribution the three differently configured TREs make as individual TREs to the T3-mediated alteration in SERCa2 transcription and in which way they may interact with each other. It is of interest to determine how much each individual TRE contributes both to the transcriptional activation on ligand binding to the TR and transcriptional suppression or silencing by unliganded TR. The contribution that the individual TREs in the SERCa2 promoter make to these functions is further explored in this report.
Two separate genes encode TRs, and in addition, there are several splice variants (5, 6, 7). One of the genes codes for TR1, which binds T3 and a separate splice variant for the non-T3 binding TR2 isoform (8). The second gene encodes the T3 binding variants TRß1, TRß2, and TRß3 (9, 10, 11). TRs have a modular design, which has been well characterized. The carboxy-terminal ligand binding domain undergoes T3-induced conformational changes and interacts with coactivators and corepressors (12).
Structural analysis of the ligand binding pocket of the TR1 and TRß1 has demonstrated that the T3 ligand is an intrinsic part of the receptor structure largely buried inside the protein fold (13). It appears therefore likely that the binding of a modified T3 analog may have an influence on the configuration of the T3 receptor surface, especially in the regions in which coactivators and corepressors bind. The most noted examples of this are the selective estrogen receptor modulators such as tamoxifen and raloxifene (14). Recently novel thyroid hormone analogs like the compound GC-1 have been synthesized, and it has been demonstrated that administration of GC-1 to hypothyroid and euthyroid animals has effects that are distinct from those of T3 (15, 16).
Although it is difficult to predict a higher-order structure of chromatin in the region of these differently configured TREs in the SERCa2 promoter, individual mutation has led to some insight into which role each TRE may play. For example, binding on a direct repeat spaced by four nucleotides favors TR/retinoid X receptor (RXR) heterodimer binding with the RXR binding to the 5' half-site (17). In contrast, binding to inverted palindromes prefers homodimeric T3 receptor configurations, and on some of these elements, the T3 ligand leads to transcriptional repression (18). This half-site-dependent characteristic of each TRE may be enhanced by binding of a modified ligand. Therefore, we compared the transactivation behavior of the novel T3 analog GC-1 and T3 with TRs bound to the DR4 vs. inverted palindromic TREs of the SERCa2 promoter. We noticed significant differences in T3 vs. GC-1 transactivation activity with TR bound to the differently configured TREs, which was independent of the TR isoform that was cotransfected. Using chromatin immunoprecipitation (ChIP) assays, we studied cofactor association on the isolated TRE3 and TRE1 within the SERCa2 promoter. Our results may provide a mechanism for the differential transactivation activity observed with T3 and GC-1 on these elements.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Cloning of the rat SERCa2 promoter up to position –3260 bp
The 3.2rSERCa2-luciferase construct was engineered by first digesting an insert (–3260 to +74 SERCa2 promoter) from 3.2pBLCAT3 (19) with HindIII. This fragment was subsequently blunt ended, digested with XhoI, and cloned into a luciferase-containing vector (pGL2, Promega, Madison, WI) previously digested with MluI, blunted with Klenow-polymerase, and digested with XhoI. The insert and the vector were ligated by using standard cloning methods. The 0.6rSERCa2-luciferase was constructed by digesting an insert (–560 to +74 SERCa2 promoter) from 0.6pBLCAT3 (19) also with HindIII. This insert was treated the same way as above and ligated to the vector pGL2 also digested with MluI, blunt ended with Klenow-polymerase, and digested with XhoI.
Mutation of the individual TREs in the rat SERCa2 promoter
The two guanines present in all TRE half-sites have been shown to be essential for receptor/DNA binding (20), independently of the ligand, and their substitution by adenosines completely abrogates receptor/DNA binding. Consequently we performed the same substitutions in all SERCa2 TREs to determine the individual contributions of those elements in SERCa2 promoter responsiveness to T3/GC-1. This was achieved by introducing point mutations by a Kunkel-based method. In brief, the SERCa2 promoter fragment encompassing +74 to –561 bp was inserted into the multiple cloning site of a M13 vector, which was used to transform a bacterial host strain deficient for deoxyuridine triphosphatase and uracil-N-glycosylase, which results in occasional substitutions of uracil for thymine in newly synthesized DNA. Subsequently the substitution of uracil for thymine in newly synthesized DNA was annealed to a set of primers containing the desired mutations, targeting simultaneously both TRE half-sites (TRE1 = primer 1; TRE2 = primer 2; TRE3 = primer 3; see Table 1
and Fig. 1 for sequence information). After annealing, the second strand was synthesized by T7 DNA polymerase and T4 DNA ligase. Finally, the double-stranded DNA was used to transform an uracil-N-glycosylase+ bacterial strain, which eliminates the wild-type strand. By using this method it was possible to generate SERCa2 promoters presenting TREs 1, 2, and 3 individually mutated. The different SERCa2 promoter TRE mutant combinations in the same promoter were accomplished by standard cloning procedures, using unique endonuclease restriction sites, flanking the three TREs (HindIII at –559 bp, ApaI at –395 bp and SmaI at –278 bp).
|
|
) within the luciferase gene. The plasmid T4T was constructed by cloning the annealed primers 9 and 10 (Table 1) into a plasmid that contained a minimal promoter of the human ß-retinoic acid receptor gene including the TATA-box upstream of the luciferase gene (21). Construction of the individual TREs upstream of the SERCa2 minimal promoter was done using the plasmid pGL2 basic as a vector backbone. The rat SERCa2 promoter from position –38 to +32 (19) was cloned into pGL2 basic, and the three SERCa2 TREs were cloned upstream of this promoter as annealed oligonucleotides with the following primers from Table 1: TRE1, primer 11/primer 12; TRE2, primer 13/primer 14; and TRE3, primer 15/primer 16. To generate the TRE swap mutants, we used a bidirectional PCR strategy in which an oligo was annealed to the sequences immediately upstream of the 5' TRE half-site and that had a mismatching extension reaching to the middle of the spacer of the TRE to be changed. Another oligo was annealed immediately downstream of the 3' half-site and extended also to the middle of the spacer of the TRE to be changed. As a template, the –0.6rSERCa2 tk-Luc circular plasmid was used with Pfu polymerase (Stratagene, La Jolla, CA). After PCR, DpnI treatment was used to select against parental DNA molecules, and the new strands, containing the swapped TREs, were ligated with T4-DNA ligase. The recircularized vector DNA incorporating the desired mutations was transformed into Escherichia coli. To change TRE1 to TRE3, we used a sense oligo primer 4 and antisense oligo primer 5 (Table 1). To change TRE3 to TRE1, we used as sense oligo primer 6 and as antisense primer 7. The mismatched bases are shown in Table 1 (lower case).
Other plasmids
Expression plasmids for transient transfections were all prepared by standard techniques using a QIAGEN Maxiprep kit. The rat cDNAs for TR1, TRß1, and human RXR were cloned into the expression plasmid pCMX.
Transient transfection of neonatal myocytes
Neonatal myocytes from 1- to 2-d-old rats were prepared as described earlier (19). For transient transfections these primary cultures were maintained in DMEM containing 5% fetal bovine serum stripped of hormones (OMEGA Scientific, Tarzana, CA). Cells (100,000 per well of a 6-well plate) were transfected with a total of 4 µg DNA using the calcium phosphate coprecipitation technique. Per well 100 ng of reporter plasmid, 250 ng pCMX-TR ( or ß) or empty expression vector for controls, 10 ng pCMX RXR, 3 µg pBKS II (for efficient transfection as a carrier plasmid), and 650 ng ß-galactosidase (ß-gal) reporter plasmid to control for transfection efficiency were coprecipitated and added to the cell culture for 16 h. After that, the culture medium was changed and replaced with fresh medium containing no ligand, T3, or GC-1 at 10–7 M final concentration. Cell culture was continued for another 30 h after which cells were washed on the plate with PBS and harvested for luciferase assays and ß-gal assays or treated with 1% formaldehyde for ChIP assays. All experiments were repeated at least three times, and data points were collected in duplicates for each experiment and normalized to the ß-gal values. Evaluation and statistical analyses were done using the Microsoft Excel program with the Student t test function (Microsoft Corp., Redmond, WA).
ChIP assays
The ChIP assays were performed according to the protocols of Upstate Biotechnology (Lake Placid, NY) with some modifications. Neonatal myocytes were transfected with 100 ng luciferase reporter per well of a 6-well plate, 250 ng of expression vector for TRß, and 10 ng of expression vector for RXR using Polyfect reagent (QIAGEN) and cultured as described above. After no treatment or treatment with T3 or GC-1 at 10–7 M final concentration, cells were cross-linked with 1% formaldehyde for 15 min at room temperature. Cells were collected by washing twice with ice-cold PBS and centrifuged for 4 min at 1000 x g. Cell pellets were resuspended in 250 µl of cell lysis buffer [50 mM Tris-HCl (pH 8.0), 85 mM KCl, and 0.5% Nonidet P-40] with protease inhibitor (Roche Molecular Biochemicals, Indianapolis, IN), incubated on ice for 10 min, and centrifuged for 4 min at 2000 x g. The pellets were resuspended in 250 µl of sodium dodecyl sulfate (SDS) lysis buffer [1% SDS, 10 mM EDTA, and 50 mM Tris-HCl (pH 8.1)] with protease inhibitor and sonicated four times for 15 sec each time followed by centrifugation at 14,000 x g for 10 min. Supernatants were collected and diluted 10-fold with dilution buffer [0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl (pH 8.1), and 167 mM NaCl] with protease inhibitor followed by preclearing with 2 µg of sheared salmon sperm DNA and protein A/G agarose [50 µl of a 50% slurry in 10 mM Tris-HCl (pH 8.1)-1 mM EDTA] for 2 h at 4 C.
Immunoprecipitation with the following antibodies was performed at 4 C overnight: anti-nuclear receptor corepressor (NCoR) (sc-8994), anti-histone deacetylase (HDAC)3 (sc-11417), anti-steroid receptor coactivator (SRC)-1 (sc-8995), and normal rabbit IgG (sc-2027) (Santa Cruz Biotechnology, Santa Cruz, CA). Immunoprecipitated complexes were collected with protein A/G agarose beads followed by sequential washes in low-salt wash buffer [0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl (pH 8.1), 150 mM NaCl], high-salt wash buffer [0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl (pH 8.1),and 500 mM NaCl], LiCl wash buffer [0.25 M LiCl, 1% Nonidet P-40, 1% deoxycholate, 1 mM EDTA, 10 mM Tris-HCl (pH 8.1)], and Tris-EDTA buffer. Precipitates were eluted with elution buffer (1% SDS, 0.1 M NaHCO3), and 5 M NaCl to a final concentration of 200 mM were added to reverse cross-links at 65 C for 6 h. DNA fragments were purified with a PCR purification kit (QIAGEN). A total of 0.5 to 3 µl of purified sample was used in 23 to 28 cycles of PCR. The (forward) primer for the pT81luc reporter plasmid was primer 17 (Table 1) and (reverse primer) for the SERCa2 promoter primer 18 (Table 1).
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
shows the position of the TREs within 500 bp upstream of the transcription start as well as the orientation, sequence, and mutation of the half-sites in each TRE. Figure 2 demonstrates that the overall stimulation observed with T3 in neonatal myocytes was similar for the 3.2 and 0.6 kb of rat SERCa2 5'-flanking DNA linked to luciferase. In these experiments we observed a relatively high basal activity of the 0.6 kb SERCa2 regulatory region that may obscure the subtle differences in activity upon mutation of individual TREs. We therefore linked the SERCa2 regulatory region containing all three TREs to the heterologous tk promoter present in the vector pT81luc. This reduced the basal level about 4-fold and enhanced the relative repression and activation by the three SERCa2 TREs 3- to 4-fold, as shown in Fig. 2. We also noted that TR1 and TRß1 had the same stimulating or silencing activity in our experimental setup using neonatal myocytes (data not shown).
|
). Elimination of TRE1 results in a SERCa2 promoter termed M1. This promoter retains TR-induced silencing but loses responsiveness to T3 by TR-induced transcriptional stimulation, indicating that TRE1 mediates to a large extent and is necessary for the positive T3 action on the wild-type SERCa2 regulatory region. Elimination of TRE2 (M2) or TRE3 (M3) still shows significant T3 receptor mediated silencing and also T3-induced transcriptional activity, however, to a significantly diminished degree. Mutation of all three TREs (M1, M2, and M3) eliminated TR silencing and T3-induced transcriptional activity, which was expected. Thus, all three elements contribute to both silencing and induction, although only one element (TRE1) is absolutely required for induction.
|
shows that when TRE1 is present as the only functional TRE in the SERCa2 promoter construct termed M2,3, the silencing effect of the unoccupied TR and the TR plus T3 transcriptional stimulatory effect is preserved. Thus, TRE2 and TRE3 contribute to the induction because they suppress the actions at TRE1, an effect that is lost when neither TRE2 nor TRE3 is present. In contrast, when TRE2 is the only functional TRE as it occurs in the M1,3 construct, the silencing and T3 plus TR stimulatory functions are abolished, indicating that TRE2 can function along with only one or two other elements. When TRE3 is the only functional TRE, a modest but significant silencing and stimulatory effect is preserved.
|
shows the effect of GC-1 in transient transfections with the wild-type and mutant SERCa2 regulatory region. Whereas the wild-type and M2,3 mutant were stimulated by T3 and GC-1 to a similar extent, M1,3 and M1,2 showed significant silencing in the presence of GC-1; by contrast, T3 showed no effect on TRE2 and stimulated TRE3. The silencing ranged from one half on TRE2 to one fifth on TRE3 in comparison with the basal activity of the same TREs. To determine whether the difference between T3 and GC-1 effects were dependent on the position of TRE3 in the SERCa2 regulatory region and relative to the other TREs was addressed by swap mutants. In S3-2-1 the order of the TREs was reversed, and this construct showed a higher basal level, compared with the wild-type or the other mutants, but could be repressed to the same level with unliganded TR. Both T3 and GC-1 could stimulate this construct about 4-fold above the repressed level. When TRE3 was placed at the position of TRE1 and the other two TREs were mutated (S3M2,3, Fig. 4), silencing by unliganded TR was abolished, and no stimulation with T3 could be observed. However, silencing in the presence of GC-1 was evident, although somewhat weaker than when TRE3 resides in its natural position.
To further elucidate the functions and separate them from the influence of surrounding elements, the individual TREs were placed in front of a minimal SERCa2 promoter as described in the experimental procedures. Figure 5 illustrates results of transient transfections of these constructs into neonatal myocytes. TRE1 showed repression by the unliganded receptor and stimulation by T3 and GC-1, similar to that observed with TRE1 present as the only functional TRE in the SERCa2 5' flanking region, although repression and activation from this minimal promoter element were decreased relative to the element present in the context of the SERCa2 regulatory region. TRE2 had no silencing activity with the unliganded TR and no T3 plus TR stimulating activity but mediated GC-1-dependent repression in agreement with the results in which TRE2 was the only functional TRE in the SERCa2 5' flanking region. TRE3 upstream of the minimal SERCa2 promoter showed modest silencing with unliganded TR but was not statistically significant. Significant silencing was mediated by GC-1, whereas T3 stimulated this construct, in line with the results of the M1,2 mutant in the SERCa2 5' flanking region. The T4T construct was included as an unrelated control to show that on a synthetic DR+4 linked to a heterologous promoter both T3 and GC-1 have agonist function. Similar synthetic constructs with inverted palindromic half-sites spaced by four or six nucleotides showed T3 and GC-1 stimulation and thus no GC-1-dependent repression (data not shown).
|
). Anti-HDAC3 and anti-NCoR antibodies precipitated both elements in a similar pattern. Lysates from nontransfected cells, cells in which TR was omitted, or immunoprecipitation with a control antiserum did not lead to an amplified PCR product. In the absence of T3 and GC-1, both TRE1 and TRE3 associated with NCoR- and HDAC3-containing complexes. The association with NCoR and HDAC3 was diminished with T3 and GC-1 on TRE1 but only with T3 on the TRE3. On TRE3, NCoR and HDAC3 associations were slightly enhanced in the presence of GC1, which is consistent with the luciferase results in Figs. 4 and 5 in which GC-1 led to repression of TRE3. In a reciprocal experiment with anti-SRC-1 antibodies, we found that in the absence of ligand, very little SRC-1 was associated with both TREs. In the presence of T3, both elements contained complexes with SRC-1; however, only TRE1 bound an SRC-1 containing complex with GC-1, whereas TRE3 did not bind SRC-1 in the presence of GC-1. These results are also consistent with the transactivation behavior of both ligands in the luciferase assays. Immunoprecipitation with anti-silencing mediator of retinoic acid and thyroid hormone receptor, anti-transducin ß-like 1 protein (TBL-1), anti-HDAC1, and anti-HDAC2 antibodies did not bring down any elements above the background level (data not shown). Removal of a small aliquot (20 µl of 1 ml lysate) of the cross-linked lysate before immunoprecipitation served as an input control for the presence of the reporters in the lysate and consistently yielded a PCR product. A schematic is presented to illustrate the T3- or GC-1 mediated association of coactivators or corepressors on TRE1 and TRE3 (Fig. 6B).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
gene, Xenopus TRßA gene, and the HIV-1 LTR genes, have been described previously (23, 24, 25, 26, 27). A systematic analysis of the individual TREs and their functional interaction in these promoters has not yet been fully explored. Here we attempted to define the role of the individual SERCa2 TREs within the promoter context or isolated upstream of a minimal promoter. In addition, we present somewhat surprising results on the ability of T3 vs. GC1 to activate or suppress transcription from TRE3 of the SERCa2 promoter, which has the configuration of an inverted palindrome.
Our results, that both T3 and GC-1 stimulate the wild-type SERCa2 regulatory region to the same extent, indicate that at a concentration of 10–7 M of ligand, both ligands can enter the neonatal myocytes and elicit similar transactivation function through TR or TRß. This is not unexpected because it was shown previously (28) that at 10–7 M, the binding of both ligands to TR and TRß were similar. We did notice a stronger stimulation of the wild-type SERCa2 promoter by GC-1 through the TRß receptor, compared with the TR receptor, at lower ligand concentrations (data not shown). However, GC-1-specific repression via TRE2 and TRE3 was only marginal at lower ligand concentrations and was maximal at 10–7 M.
Mutation of single TREs in the SERCa2 regulatory region suggests that a higher-order structure exists, involving complexes on all three TREs. This structure seems to be dependent on TRE1 for recruitment of coactivator complexes because TRE2 and TRE3 together mediate only repression by unliganded and liganded TRs as shown in Fig. 3. This is in contrast to the results with individual TREs in which unliganded TRs repress and liganded TRs activateTRE3. A combination of TRE1 with TRE2 or TRE3 demonstrates the dominance of TRE1 for transactivation. The lower magnitude of transactivation shown with the M2 mutant could be explained by the decreased formation of the potent transactivation complex that forms on the wild-type SERCa2 regulatory region in the absence of TR binding to TRE2 or the possibility that other factors may bind to the mutated TRE2 region that could interfere with T3 signaling. Predictably mutation of all three TREs leads to loss of TR-mediated repression and ligand-activated stimulation of the SERCa2 regulatory region.
Mutation of two TREs, leaving only one functional TRE in the promoter, revealed the strong activation function potential of TRE1 and a differential effect of GC-1 compared with T3 on TRE2 or TRE3. This suggests that all three TREs together assemble a higher-order structure of TRs and their cofactors in which TRE2 and TRE3 function in the context of the entire promoter to modulate TRE1 function in an inhibitory role but that allows optimal function for the overall promoter. The isolated TRE2 (M1,3) lacks TR-mediated repression and T3-induced transactivation but interestingly mediates GC-1-dependent silencing. This indicates that TRE2 can bind TRs, which we had shown previously (4), although the specific structure of two inverted palindromic half-sites spaced by four nucleotides has not been reported in another promoter before. The mutant M1,2 in which TRE3 is the only functional TRE, shows unliganded repression and small transactivation with T3. GC-1, in contrast, shows a strong repression, demonstrating an opposite effect to T3.
The striking difference that we observed on TRE3 with T3 and GC-1 prompted us to investigate whether the order of the TREs within the SERCa2 regulatory region or the particular position of TRE3 was important for the GC-1-specific effect. In Fig. 4 we show the results with swap mutants in which the order of the TREs was changed from 1-2-3 in the wild-type to 3-2-1 in the swap mutant S3-2-1. The repositioning of TRE3 did not change the overall profile of unliganded repression and ligand-induced transactivation with both T3 and GC-1. This shows that as long as TRE1 is present either in a distal position or a proximal position relative to the transcription start site, GC-1 functions as an agonist. The other swap mutant that we tested (S3,M2,3) placed TRE3 at the TRE1 position, whereas the other two remaining TREs were mutated. This swap eliminated the unliganded repression and T3-dependent transactivation of TRE3, possibly due to the different surrounding DNA binding factors in the SERCa2 regulatory region or the relative distance of TRE3 to the transcription start site. Interestingly, the ligand-dependent silencing by GC-1 was preserved, however, to a much smaller extent than in the natural position of TRE3.
Placing the individual TREs outside of their promoter context upstream of a minimal SERCa2 (S2) promoter, as shown in Fig. 5, mimicked their qualitative function within the promoter. These results showed that the TREs did not need the neighboring DNA binding factors in the SERCa2 regulatory region for unliganded repression or ligand-dependent activation and silencing, which was observed in the intact promoter.
To provide a mechanistic explanation for the differential GC-1 vs. T3-dependent silencing mediated by TRE3, we compared the composition of coactivator and corepressor complexes of TRE1 and TRE3 alone within the promoter context by ChIP of transient transfected plasmid reporters (29) in primary cultures of neonatal cardiac myocytes. Figure 6A shows that the complex assembled on TRE1 contained very little or no SRC-1 in the absence of ligand but associated with SRC-1 in the presence of T3 and GC-1. This is consistent with the agonist function of both ligands shown in Fig. 4. In contrast, TRE3 did not associate with SRC-1 in the presence of GC-1 but did associate in the presence of T3. This is also consistent with the differential GC-1- vs. T3-dependent silencing observed with M1,2 shown in Fig. 4. ChIP assays with the corepressor antibody for NCoR and the histone deacetylase antibody for HDAC3 paralleled each other. Here we observed a good association of both proteins, NCoR and HDAC3, in the absence of ligand on TRE1 and TRE3, consistent with the finding that both mutants M2,3 and M1,2 show unliganded TR-mediated silencing. The association with NCoR and HDAC3 is weakened in the presence of T3 and GC-1 on TRE1. On TRE3, however, only T3 weakened NCoR and HDAC3 association, whereas GC-1 appeared to increase NCoR and HDAC3 binding to the TRE3 complex. The functional consequence of these observations would be a GC-1-dependent silencing on TRE3 but not on TRE1, which is what we observed with M2,3 and M1,2, shown in Fig. 4. It is of interest to note that GC-1 largely behaves as a T3 agonist but recruits corepressors to the complex formed on isolated TREs configured as inverted palindromes.
The most likely explanation for the different effects of T3 and GC-1 rests with the structural divergence between the two molecules and possible changes in the surface of the TR that are induced when T3 or GC-1 occupies the ligand binding pocket. The T3 ligand forms an intimate part of the occupied TR structure, and a ligand with a different structure from T3, such as GC-1, will make different contacts with amino acid residues that line the ligand binding pocket. Indeed, on the basis of crystal structures, different contacts between the GC-1/TR complex and the T3/TR complex have been described (13). However, the surfaces of the T3 and GC-1 liganded TR ligand binding domains are identical in the crystal structures. Thus, it seems likely that differences in the interactions between the two ligands with the TR ligand binding domain result in differences in the surfaces of the receptor responsible for coactivator or corepressor recruitment that are not apparent in the static x-ray crystal structures but occur in the dynamic setting of receptor function. To our knowledge, this phenomenon has not been reported for other nuclear receptors but has major implications for selective modulation of their functions. Selective modulation in other contexts, such as with the selective estrogen receptor modulators, has involved rather major differential effects of the ligand on the placement of helix 12 that is readily apparent in the x-ray crystal structure result in major differential effects. By contrast, the more subtle effects observed here are likely to involve more subtle differences in the actions of ligands. Whether this explains the differential actions of GC-1 vs. T3 in animals, i.e. on triglyceride levels, is not known; however, the differential actions of two ligands that do not impart structural changes that can be detected by static x-ray crystal structures deserve further study. There is also a possible contribution of the different ligands to structural changes of homodimers or heterodimers bound to different half-site configurations, which has been suggested previously (30). The differences in half-site sequence and the structure of the TRE itself could alter receptor dimerization or cofactor recruitment with T3 vs. GC-1, and we look forward to studies involving crystal structure data with the full-length receptors bound to various TREs in the presence and absence of ligands. Here we show a combination of a ligand-induced and individual TRE-dependent effect of a thyroid hormone analog, GC-1, that acts as an agonist on a classical DR4 element but as an antagonist on TRE3 configured as an everted repeat.
|
Acknowledgments |
|---|
|
Footnotes |
|---|
Current address for B.G.: Duke University Medical Center, Department of Neurobiology, Box 3209, Durham, North Carolina 27710.
First Published Online August 4, 2005
Abbreviations: ChIP, Chromatin immunoprecipitation; ß-gal, ß-galactosidase; HDAC, histone deacetylase; NCoR, nuclear receptor corepressor; RXR, retinoid X receptor; SDS, sodium dodecyl sulfate; SERCa2, sarcoendoplasmic reticulum calcium ATPase; SRC, steroid receptor coactivator; tk, thymidine kinase; TR, T3 receptor; TRE, T3 response element.
Received May 26, 2005.
Accepted for publication July 26, 2005.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
and ß thyroid hormone receptors from thyrotrope cells: the mouse pituitary-specific ß2 isoform differs at the amino terminus from the corresponding species from rat pituitary tumor cells. Mol Endocrinol 5:1049–1061[Abstract]
-thyroid hormone receptor gene. J Biol Chem 264:8900–8904-related protein which binds deoxyribonucleic acid but does not bind thyroid hormone. Mol Endocrinol 2:893–901[Abstract]
gene expression in cardiac myocytes. Delineation of cis-active DNA elements that confer responsiveness to thyroid hormone but not to retinoic acid. J Biol Chem 266:8638–8646 gene expression through elements in the promoter and first intron. J Biol Chem 275:34989–34997This article has been cited by other articles:
 |
|
 |
|
  L. F. R. Velasco, M. Togashi, P. G. Walfish, R. P. Pessanha, F. N. Moura, G. B. Barra, P. Nguyen, R. Rebong, C. Yuan, L. A. Simeoni, et al. Thyroid Hormone Response Element Organization Dictates the Composition of Active Receptor J. Biol. Chem., April 27, 2007; 282(17): 12458 - 12466. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M Villicev, F. R S Freitas, M. S Aoki, C. Taffarel, T. S Scanlan, A. S Moriscot, M. O Ribeiro, A. C Bianco, and C. H A Gouveia Thyroid hormone receptor {beta}-specific agonist GC-1 increases energy expenditure and prevents fat-mass accumulation in rats J. Endocrinol., April 1, 2007; 193(1): 21 - 29. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. B. Harvey, J. H. D. Bassett, P. Maruvada, P. M. Yen, and G. R. Williams The Rat Thyroid Hormone Receptor (TR) {Delta}{beta}3 Displays Cell-, TR Isoform-, and Thyroid Hormone Response Element-Specific Actions Endocrinology, April 1, 2007; 148(4): 1764 - 1773. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Flamant, K. Gauthier, and J. Samarut Thyroid Hormones Signaling Is Getting More Complex: STORMs Are Coming Mol. Endocrinol., February 1, 2007; 21(2): 321 - 333. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
